Table 1.
DENV-2/ZIKV/WNV replication inhibitory effect.
| DENV-2 |
ZIKV |
WNV |
|||||
|---|---|---|---|---|---|---|---|
| Cpd. | CC50a (μM) | IC50b (μM) | SIc | IC50 (μM) | SI | IC50 (μM) | SI |
| 6a | 84.0 | 9.3 ± 4.2 | 9 | 14.7 ± 5.7 | 6 | ND | – |
| 6b | 136.0 | 29.8 ± 0.3 | 5 | 8.9 ± 0.9 | 15 | ND | – |
| 6c | 200.0 | 12.0 ± 0.2 | 17 | 2.9 ± 0.9 | 68 | ND | – |
| 6d | 200.0 | 18.0 ± 12.2 | 11 | 8.0 ± 1.5 | 25 | ND | – |
| 6e | 200.0 | 17.5 ± 7.3 | 11 | 6.2 ± 2.5 | 32 | ND | – |
| 6f | 100.0 | NAd | – | 8.2 ± 1.5 | 12 | ND | – |
| 6g | 200 | 3.5 ± 4.0 (4.9 ± 2.6)f |
57 41 |
ND | – | ND (NA)f |
– |
| 6h | 50.0 | 4.5 ± 0.2 | 11 | 10.6 ± 0.5 | 5 | ND (1.9 ± 2.9)f (1.5 ± 1.3)g |
– 26 33 |
| 6i | 200.0 | 2.6 ± 0.3 (NA)f (0.9 ± 0.04)g |
77 - 222 |
1.1 ± 0.4 (0.8 ± 0.3)f (0.5 ± 0.32)g |
182 250 400 |
ND (NA)f (3.9 ± 0.67)g |
– – 51 |
| 6j | 200.0 | NA | – | 25.0 ± 7.1 | 8 | ND | – |
| 6k | 7.5 | ND | - | ND | – | ND | – |
| 6l | 200.0 | NA | – | 33.5 ± 7.6 | 6 | ND | – |
| 6m | 200.0 | 28.2 ± 3.9 | 7 | 29.0 ± 4.8 | 7 | ND | – |
| 8a | 8.0 | ND | - | ND | – | ND | – |
| 8b | 6.0 | ND | - | ND | – | ND | – |
| Sofosbuvir | 200.0 | 4.7 ± 0.7 (4.6 ± 1.4)f (3.8 ± 1.1)g |
42 43 53 |
3.2 ± 0.7 (2.7 ± 0.5)f (2.0 ± 1.1)g |
62 74 100 |
ND (1.7 ± 0.5)f (1.2 ± 0.3)g |
– 117 166 |
| Ribavirin | 200.0 | 4.0 ± 0.6 (7.6 ± 1.2)f (4.1 ± 0.6)g |
50 26 49 |
4.4 ± 0.6 (3.8 ± 0.6)f (2.2 ± 0.6)g |
45 53 91 |
ND (9.5 ± 4.0)f (6.7 ± 0.6)g |
– 21 30 |
aCC50: half-maximal cytotoxic concentration (μM); bIC50: half-maximal inhibitory concentration calculated through SYRA; each value is the mean of three experiments ± standard deviation (SD); cSI: selectivity index (SI = CC50/IC50). dNA: not active; eND: not determined; fIC50: half-maximal inhibitory concentration calculated through DYRA; gIC50: half-maximal inhibitory concentration calculated through PRA. DMSO was used as control in all cytotoxicity and antiviral assays.